VRS now offers antiviral testing services for alpha herpesviruses HSV-1 and HSV-2.
Most people (60–65%) will be infected with HSV-1 over their lifetime, and HSV-2 infection is present in around 10–11%. Once considered little more than a benign nuisance, herpes simplex viruses are now implicated in conditions far beyond cold sores. Recent research links them to Alzheimer’s disease and HIV susceptibility. Because of this, HSV-1 and HSV-2 are now the focus of renewed therapeutic attention.
For teams developing HSV therapeutics, we now offer robust antiviral efficacy and virus neutralisation assays for both HSV-1 and HSV-2. These testing services are fully validated and benchmarked against well-characterized internal controls. This means you can skip months of in-house setup and start generating data right away.
Contact us to learn more about our HSV assays and how we can help accelerate your research program.
